Protect Yourself While There’s Still Time …

The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.

4 simple steps to protect your privacy and money before it’s too late.

Rock Soffer Biography and Net Worth

Director of Longeveron

Rock Soffer joined Longeveron’s Board of Directors in March 2020. Mr. Soffer is President, Special Project Division at Turnberry Associates, where he oversees leasing, asset acquisitions, zoning and site approvals, as well as the development of other specialty projects. He has experience in managing and securing financing for complex projects, as well as overseeing a number of developments in Florida, such as the redevelopment of an almost 200,000 square-foot open-air lifestyle shopping center in Aventura. In addition, Mr. Rock Soffer was tasked with overseeing the referendum for the new 800-key Miami Beach Convention Center luxury hotel. Upon completion, the privately-funded property will be the cornerstone of the Convention Center District in Miami Beach. Mr. Rock Soffer is an advocate for responsible, environmentally sustainable development. He is actively involved in his local community and sits on the boards of AYITI Community Trust, and the Institute of Contemporary Art Miami.

What is Rock Soffer's net worth?: The estimated net worth of Rock Soffer is at least $364,934.50 as of April 11th, 2024. Mr. Soffer owns 208,534 shares of Longeveron stock worth more than $364,935 as of April 26th. This net worth estimate does not reflect any other investments that Mr. Soffer may own. Learn More about Rock Soffer's net worth.
How do I contact Rock Soffer?: The corporate mailing address for Mr. Soffer and other Longeveron executives is 1951 NW 7TH AVENUE SUITE 520, MIAMI FL, 33136. Longeveron can also be reached via phone at 305-302-7158 and via email at [email protected]. Learn More on Rock Soffer's contact information.
Has Rock Soffer been buying or selling shares of Longeveron?: During the last quarter, Rock Soffer has bought $75,000.25 in shares of Longeveron stock. Most recently, on Thursday, April 11th, Rock Soffer bought 31,915 shares of Longeveron stock. The stock was acquired at an average cost of $2.35 per share, with a total value of $75,000.25. Following the completion of the transaction, the director now directly owns 208,534 shares of the company's stock, valued at $490,054.90. Learn More on Rock Soffer's trading history.
Who are Longeveron's active insiders?: Longeveron's insider roster includes James Clavijo (CFO), Geoff Green (CEO), Joshua Hare (Insider), Paul Lehr (General Counsel), and Rock Soffer (Director). Learn More on Longeveron's active insiders.
Are insiders buying or selling shares of Longeveron?: During the last year, Longeveron insiders bought shares 5 times. They purchased a total of 150,436 shares worth more than $370,049.60. During the last year, insiders at the sold shares 2 times. They sold a total of 1,353 shares worth more than $47,234.40. The most recent insider tranaction occured on April, 11th when CEO Mohamed Wa'el Ahmed Hashad bought 10,638 shares worth more than $24,999.30. Insiders at Longeveron own 24.3% of the company. Learn More about insider trades at Longeveron.
Information on this page was last updated on 4/11/2024.

Rock Soffer Insider Trading History at Longeveron

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/11/2024	Buy	31,915	$2.35	$75,000.25	208,534
5/23/2022	Sell	800	$77.80	$62,240.00	67,635
5/20/2022	Sell	750	$80.60	$60,450.00	68,435
10/13/2021	Buy	1,200	$37.60	$45,120.00
10/11/2021	Buy	390	$34.50	$13,455.00
2/12/2021	Buy	10	$80.50	$805.00

Rock Soffer Buying and Selling Activity at Longeveron

Longeveron Company Overview

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young, healthy adult donors. It is conducting Phase 1, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.

Today's Range

Now: $1.75

$1.62

$1.79

50 Day Range

MA: $3.69

$1.67

$5.79

2 Week Range

Now: $1.75

$1.60

$44.00

Volume

371,931 shs

Average Volume

1,623,746 shs

Market Capitalization

$4.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.21